Endocyte (ECYT) in Focus: Stock Tanks 14% - Tale of the Tape

Endocyte, Inc. ECYT saw a big move last session, as the company's shares fell by nearly14% on the day. The move came on pretty good volume too with far more shares changing hands than in a normal session. This reverses the most recent trend for ECYT as the stock is now up around 7.6% since June 3, 2014.

The company has seen a flat track record when it comes to current year estimate revisions over the past few weeks. However, the consensus for loss estimates has narrowed. This recent price action is discouraging, so make sure to keep a close watch of this firm in the near future, and especially on earnings estimates following the recent slump.

ECYT currently has a Zacks Rank #3 (Hold) while its Earnings ESP is positive.

Some better-ranked stocks in the healthcare sector include Aeolus Pharmaceuticals Inc. (AOLS), Aerie Pharmaceuticals, Inc. AERI and Ariad Pharmaceuticals Inc. ARIA. All these stocks hold a Zacks Rank #2 (Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.

Click to get this free report

ENDOCYTE INC ECYT: Free Stock Analysis Report

AEOLUS PHARMACT (AOLS): Get Free Report

AERIE PHARMACT AERI: Get Free Report

ARIAD PHARMA ARIA: Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

Market News and Data brought to you by Benzinga APIs